<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04015531</url>
  </required_header>
  <id_info>
    <org_study_id>RT 1901</org_study_id>
    <nct_id>NCT04015531</nct_id>
  </id_info>
  <brief_title>Hypofractionated Versus Conventional Fractionation Radiotherapy</brief_title>
  <official_title>Hypofractionated Versus Conventional Fractionation Radiation After Conservative Surgery or Mastectomy With Irradiation of Lymph Node Drainage: a Phase II Randomized Clinical Trial for the Evaluation of Acute Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital da Baleia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital da Baleia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the acute toxicity and quality of life of
      hypofractionated radiation versus conventional when regional node irradiation is indicated
      after breast-conserving surgery or mastectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators hypothesize that hypofractionated radiotherapy is equal effective and safe as
      conventional radiotherapy in breast cancer patients undergoing regional nodal irradiation.

      Eligible breast cancer patients are randomized 1:1 into the following two groups:

        1. Hypofractionated therapy: 40 Gy in 15 fractions of 2.67 Gy in breast or chest wall and
           nodal drainage with Concurrent boost 48.0 Gy / 3.2 Gy daily in tumor bed, in case of
           conservative surgery;

        2. Standard fractionation: 50 Gy in 25 fractions in breast or chest wall and nodal drainage
           with sequential tumor bed boost with 10 Gy in 5 fractions in tumor bed in case of
           conservative surgery.

      Patients will be followed for 6 months after radiotherapy to evaluate acute toxicity and
      quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Radiation toxicity will be analysed by a blind second investigator.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CTCAE Toxicity Assessement - Acute Toxicity</measure>
    <time_frame>Before treatment, every week of treatment (week 1 to 3 or 1 to 5-6, according to the treatment arm), at the end of treatment (week 3 or week 5-6, according to the treatment arm), 4, 8 and 24 weeks after the last fraction received.</time_frame>
    <description>Change in acute toxicity will be assessed according to criteria of CTCAE version 4.03.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EORTC QLQ-C30 (version 3)</measure>
    <time_frame>Before treatment, at the end of treatment (week 3 or week 5-6, according to the treatment arm),1 and 6 months after last fraction received.</time_frame>
    <description>Patients' quality of life will be assessed using self-administered questionnaire EORTC-QLQ-C30 (version 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EORTC breast cancer module (BR23)</measure>
    <time_frame>Before treatment, at the end of treatment (week 3 or week 5-6, according to the treatment arm),1 and 6 months after last fraction received.</time_frame>
    <description>Patients' quality of life will be assessed using self-administered questionnaire EORTC breast cancer module (BR23).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Radiation Toxicity</condition>
  <arm_group>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 Gy in 25 fractions to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla), followed by tumor bed boost of 10 Gy in 5 fractions in case of breast conserving surgery.
Total time: 5-6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofractionated radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Gy in 15 fractions (2.67 Gy each) to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla).
Patients undergoing breast conserving surgery will receive concomitant boost with total dose of 48 Gy in 15 fractions (3.20 Gy each) to tumor bed.
Total time: 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional radiotherapy</intervention_name>
    <description>50 Gy / 25 fractions / 5-6 weeks / Sequential boost of 10 Gy in 5 fractions, in case of conservative surgery.</description>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
    <other_name>Standard fractionation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiotherapy</intervention_name>
    <description>40 Gy / 15 fractions / 3 weeks / Concomitant boost with total dose of 48 Gy in 15 fractions, in case of conservative surgery.</description>
    <arm_group_label>Hypofractionated radiotherapy</arm_group_label>
    <other_name>Hypofractionated therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female;

          -  Older than 18;

          -  Breast cancer stage T1 - T3;

          -  At least 1 lymph node positive;

          -  Treated with mastectomy or conservative surgery;

          -  Negative surgical margins;

          -  No distant metastasis;

          -  No supraclavicular or internal mammary nodes metastases;

          -  Adjuvant systemic therapy with chemotherapy, endocrine therapy or anti-HER2 (Human - -
             Epidermal Growth Factor Receptor 2) treatment is accepted;

          -  Signed informed consent.

        Exclusion Criteria:

          -  Positive surgical margins;

          -  Concomitant chemotherapy;

          -  Supraclavicular or internal mammary nodes metastases;

          -  Distant metastasis;

          -  Previous thoracic radiotherapy;

          -  Bilateral breast cancer;

          -  Patients with collagen diseases;

          -  Unable or unwilling to sign inform consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Oliveira B Gil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baleia Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriel Oliveira B Gil, MD</last_name>
    <phone>55 31 984463767</phone>
    <email>gabrielbgil@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Darly GS Delfino, MSc</last_name>
    <phone>55 31 971735501</phone>
    <email>darlygsoares@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, Jin J, Liu XF, Yu ZH, Ren H, Li N, Lu NN, Tang Y, Tang Y, Qi SN, Sun GY, Peng R, Li S, Chen B, Yang Y, Li YX. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):352-360. doi: 10.1016/S1470-2045(18)30813-1. Epub 2019 Jan 30.</citation>
    <PMID>30711522</PMID>
  </reference>
  <reference>
    <citation>EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848.</citation>
    <PMID>24656685</PMID>
  </reference>
  <reference>
    <citation>Duxbury PJ, Gandhi A, Kirwan CC, Jain Y, Harvey JR. Current attitudes to breast reconstruction surgery for women at risk of post-mastectomy radiotherapy: A survey of UK breast surgeons. Breast. 2015 Aug;24(4):502-12. doi: 10.1016/j.breast.2015.05.002. Epub 2015 May 26.</citation>
    <PMID>26021276</PMID>
  </reference>
  <reference>
    <citation>START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008 Apr;9(4):331-41. doi: 10.1016/S1470-2045(08)70077-9. Epub 2008 Mar 19.</citation>
    <PMID>18356109</PMID>
  </reference>
  <reference>
    <citation>Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, Chronowski GM, Dvorak T, Grade E, Hoffman KE, Kelly P, Ludwig M, Perkins GH, Reed V, Shah S, Stauder MC, Strom EA, Tereffe W, Woodward WA, Ensor J, Baumann D, Thompson AM, Amaya D, Davis T, Guerra W, Hamblin L, Hortobagyi G, Hunt KK, Buchholz TA, Smith BD. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015 Oct;1(7):931-41. doi: 10.1001/jamaoncol.2015.2666.</citation>
    <PMID>26247543</PMID>
  </reference>
  <reference>
    <citation>Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, Malin J, Emanuel EJ. Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013. JAMA. 2014 Dec 17;312(23):2542-50. doi: 10.1001/jama.2014.16616.</citation>
    <PMID>25494006</PMID>
  </reference>
  <reference>
    <citation>Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC. Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1001-9. doi: 10.1016/j.ijrobp.2014.09.032.</citation>
    <PMID>25539365</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>hypofractionated therapy</keyword>
  <keyword>nodal irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Use of a controlled access approach, with a transparent system to review requests and provide secure data access; assurance that patient privacy and confidentiality can be maintained;</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>From 2020 onwards</ipd_time_frame>
    <ipd_access_criteria>Principal investigator's e-mail</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

